Navigation Links
7 pharmaceutical companies join academic researchers to speed TB drug discovery
Date:6/25/2012

Seven pharmaceutical companies and four research institutions, working with the Bill & Melinda Gates Foundation, have launched a groundbreaking partnership that aims to speed the discovery of essential new treatments for tuberculosis (TB).

The partnership, known as the TB Drug Accelerator (TBDA), will target the discovery of new TB drugs by collaborating on early-stage research. The long-term goal of the TBDA is to create a TB drug regimen that cures patients in only one month. Existing drugs, all at least 50 years old, require six months to cure the disease a lengthy process that contributes to 20-30% of patients dropping out before completion.

Aided by nearly $20 million from the Gates Foundation, partners officially launched the TBDA in April and have begun the first round of screening for new TB drug candidates. The TBDA aims to develop five new preclinical drug candidates with treatment-shortening potential within 5 years and proof-of-concept for a one-month three-drug regimen within 10 years.

"The TB Drug Accelerator establishes a new paradigm of cooperation in drug discovery," said Sanofi Chief Executive Officer Chris Viehbacher, speaking on behalf of the pharmaceutical industry partners. "By working together on this, we can optimize our research and speed the development of one of the most pressing needs in global health."

Through this partnership, the participating pharmaceutical companies -- Abbott, AstraZeneca, Bayer, Eli Lilly, GlaxoSmithKline, Merck and Sanofi will open up targeted sections of their compound libraries and share data with each other and four research institutions: the Infectious Disease Research Institute; the National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes of Health; Texas A&M University; and Weill Cornell Medical College. Breaking from traditional research and development practices, the companies will work together to develop the best prospects, regardless of where the drug originated. The structures of lead compounds identified through the program will ultimately be placed in the public domain.

"TB drug discovery has reached a crossroads," said Dr. Carl Nathan, Professor and Chairman of the Department of Microbiology and Immunology at Weill Cornell Medical College. "Finding new and faster-acting TB drugs will take a new kind of partnership, connecting not only academia and industry, but drug company with drug company. The TB Drug Accelerator is a historic experiment in innovative collaboration."

Tuberculosis is a bacterial infection that attacks the respiratory system and other organs. It is the second leading infectious cause of death worldwide, having killed nearly 1.4 million people in 2010 alone. At any given moment, more than 12 million people around the world are suffering from active TB.

The high percentage of patients who fail to complete the current six-month treatment regimen adds significantly to the TB burden. High default rates lead to increased mortality, contribute to TB drug resistance and allow patients to continue to infect others. Shortening treatment regimens to even two months would keep an additional one million people on treatment each year.

"Innovative partnerships are critical to helping us solve the most pressing challenges of global health," said Trevor Mundel, president of the Global Health Program at the Bill & Melinda Gates Foundation. "It's our hope that the TB Drug Accelerator will set a precedent for drug discovery and serve as a resource for others."

The TBDA will add to existing collaborative efforts on TB, building a more robust drug discovery pipeline to complement other initiatives, such as Critical Pathways to TB Drug Regimens (CPTR), which works with the Global Alliance for TB Drug Development to speed the clinical development of new combination TB drug therapies.


'/>"/>

Contact: Daniel Pawson
dpawson@globalhealthstrategies.com
718-873-3169
Global Health Strategies
Source:Eurekalert

Related biology news :

1. From scourge to saint: E. coli bacteria becomes a factory - to make cheaper, faster pharmaceuticals
2. Tokai Pharmaceuticals galeterone well-tolerated in patients with advanced prostate cancer
3. New Biotech and Pharmaceutical Market Research from Global Information Inc Forecasts Strong Growth Coming Out of Recession
4. Attendees Save Up To $800 on Boston-area Pharmaceutical and Healthcare Conferences, Early Bird Discounts Expiring April 27
5. Understanding the RNAi Reagents Market Overlap with Drug Discovery and Therapeutic Development is Critical for Pharmaceutical Leaders
6. Fish show autism-like gene expression in water with psychoactive pharmaceuticals
7. AcelRx Pharmaceuticals Receives First U.S. Patent for Small-Volume Oral Transmucosal Dosage Forms
8. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
9. UC Santa Barbara researchers discover genetic link between visual pathways of hydras and humans
10. Researchers attempt to solve problems of antibiotic resistance and bee deaths in one
11. UNH researchers find African farmers need better climate change data to improve farming practices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/2/2016)... June 2, 2016 Perimeter Surveillance ... Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... will generate revenues of $17.98 billion in 2016. ... Inc, a leader in software and hardware technologies for ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only ... Center and will showcase its product’s latest features from June 26 to June ... scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... Windsor, Connecticut (PRWEB) , ... June 23, 2016 ... ... will introduce a new line of intelligent tools designed, tuned and optimized exclusively ... place September 12–17 in Chicago. The result of a collaboration among several companies ...
(Date:6/23/2016)... 23, 2016 ReportsnReports.com adds ... to its pharmaceuticals section with historic and forecast ... much more. Complete report on the ... profiling 15 companies and supported with 261 tables ... . The Global Cell Culture ...
(Date:6/22/2016)... -- Research and Markets has announced the addition of ... offering. The global biomarkers ... in 2013. The market is expected to grow at a five-year ... increasing from $50.6 billion in 2015 to $96.6 billion in 2020. ... period (2015 to 2020) are discussed. As well, new products approved ...
Breaking Biology Technology: